Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapy

Not Applicable

• Conditions: Malignant tumor (all HLA types)

• Registration Number: JPRN-UMIN000009447
• Lead Sponsor: Seta Clinic Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who have: (1)Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them (2)Serious drug allergy (3)Positive for HIV or HTLV-1 (4)Active autoimmune disease (5)Continuous systemic administration of steroids (6)Other cancers (7)Active infections (8)Pregnant or lactating (9)Serious cardiac disease (10)Any reason why, in the opinion of the investigator, the patient should not participate.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Immunological responses

Secondary Outcome Measures

Name	Time	Method
Safety Efficacy